ENLV Stock Analysis: Buy, Sell, or Hold?
ENLV - Enlivex Therapeutics Ltd. Ordinary Shares
$0.67
-0.05 (-6.80%)
▼
5d:
-5.62%
30d:
-8.51%
90d:
-35.57%
HOLD
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 29, 2026
0d
Get Alerted When ENLV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENLV shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENLV shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENLV is currently trading at $0.67, which is considered oversold relative to its 30-day fair value range of $0.69 to $0.80.
Technical Outlook: Technically, ENLV is in a strong downtrend. The price is currently testing key support at $0.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: ENLV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+2884.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENLV is in a strong downtrend. The price is currently testing key support at $0.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: ENLV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+2884.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.69 -
$0.80
Company Quality Score
50/100
(HOLD)
Options IV Signal
24th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 24th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.8%)
- BULLISH: Trading 2884.6% below Wall St target ($20.00)
- CAUTION: Recommendation downgraded due to -5.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.69 -
$0.80
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.24
(36.2%)
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.90
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.45
Wall Street Target
$20.00
(+2884.6%)
Share & Embed Analysis
Last updated: June 14, 2026 3:05 PM ET
Data refreshes hourly during market hours. Next update: 4:05 PM
Data refreshes hourly during market hours. Next update: 4:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENLV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 48 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 52 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 62 BUY |
